A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer
Status:
Recruiting
Trial end date:
2021-09-15
Target enrollment:
Participant gender:
Summary
This is an open-label, phase Ib/II, multi-center study to evaluate efficacy and safety of
KN046 alone or in combination with nab-paclitaxel in subjects with locally advanced
unresectable or metastatic triple negative breast cancer (TNBC). The study is composed of
dose escalation and expansion parts. Every subject will subject tumor tissue used for
biomarker evaluation. Each subject will receive KN046 or in combination with nab-paclitaxel
untill confirmed progressive disease, unacceptable toxicity or withdrawal of informed consent
whichever occurs first.